Drug Profile
Research programme: antibody therapeutics - Xencor
Alternative Names: PD1 x costim bispecific antibodies - Xencor; PD1 x costimulation bispecific antibodies - Xencor; XmAb 14484; XmAb 5483; XmAb bispecific x4; XmAb®5485Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; CD20 antigen modulators; CD3 antigen modulators; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3 receptor alpha subunit antagonists; Programmed cell death-1 receptor antagonists; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; B-cell lymphoma; Cancer; Haematological malignancies; Immunological disorders; Multiple myeloma; Neuroendocrine tumours; Solid tumours
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Jul 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Neuroendocrine-tumours in USA (Parenteral)